Nilofabicin - CrystalGenomics
Alternative Names: CG-400549; CG-549; Enoyl reductase inhibitors - CrystalGenomics; ERCG 0549; FabI inhibitor (CG400549) - CrystalGenomicsLatest Information Update: 28 Oct 2022
At a glance
- Originator CrystalGenomics
- Class Amines; Antibacterials; Pyridines; Pyridones; Small molecules; Thiophenes
- Mechanism of Action Enoyl ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Bacterial infections
Highest Development Phases
- Phase II Methicillin-resistant Staphylococcus aureus infections
- No development reported Staphylococcal infections; Vancomycin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections(In volunteers) in Netherlands (PO, Tablet)
- 30 Jun 2020 CrystalGenomics completes a phase-I clinical trial in Methicillin-resistant Staphylococcus aureus infections (In volunteers) in Netherlands (PO, Tablet) (NCT05393856)
- 23 Sep 2019 Phase-I clinical trials in Methicillin-resistant Staphylococcus aureus infections (In volunteers) in Netherlands (PO, Tablet) (NCT05393856)